Valneva Grants Exclusive C. difficile Vaccine License to Elaris, Confirms 2026 Guidance
Valneva granted Elaris FlexCo an exclusive global license to its VLA84 antigen technology for a next-generation C. difficile vaccine program, securing milestone payments and royalties and targeting IND-enabling development for 2027 clinical studies. The company also filed its 2025 audited consolidated results and universal registration document, confirming its financial guidance for 2026.
1. Exclusive Global License Agreement
Valneva granted Elaris FlexCo an exclusive global license to its Clostridioides difficile antigen technology, VLA84. The agreement includes customary development, regulatory and commercial milestone payments plus royalties on future net sales and supports Elaris’s plan to advance a next-generation vaccine program toward IND-enabling development and clinical studies around 2027.
2. 2025 Financial Results and 2026 Guidance
Valneva filed its audited consolidated financial results for the year ended December 31, 2025, along with its universal registration document. The company confirmed its financial guidance for 2026, reinforcing its strategic outlook and compliance with regulatory requirements.